Vanguard Group Inc. Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vanguard Group Inc. lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,709,510 shares of the company's stock after purchasing an additional 6,257 shares during the quarter. Vanguard Group Inc. owned 11.86% of IDEXX Laboratories worth $4,014,300,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of IDXX. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories in the third quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories in the 4th quarter worth $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the fourth quarter worth $41,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Down 1.6 %

IDEXX Laboratories stock traded down $6.67 during mid-day trading on Friday, reaching $415.87. 470,167 shares of the company traded hands, compared to its average volume of 581,913. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The firm has a market capitalization of $33.71 billion, a price-to-earnings ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. The firm's 50 day moving average price is $437.07 and its 200 day moving average price is $443.27.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently commented on IDXX. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price on the stock. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.